Summary
Congestive heart failure is an increasingly common patient problem. It is a multisystem disease that involves not only the heart but also the kidneys and neurohormonal systems. Any treatment for heart failure should address depressed contractility and exercise intolerance, as well as control compensatory mechanisms. There are many different approaches to the treatment of congestive heart failure: among the drugs used are diuretics, digitalis compounds, nitrates, calcium channel blockers, β-blockers, β-agonists, vasodilators, angiotensin-converting enzyme (ACE) inhibitors and the new phosphodiesterase inhibitors. The therapy usually involves a multiple drug treatment plan to achieve the maximum effect for the patient with the lowest incidence of side effects. Heart failure involves a large spectrum of patients with left ventricular dysfunction, and success at achieving treatment goals with these patients will vary with the severity of that symptom. A major concern is that increasing contractility may further damage the myocardium and shorten the survival of these patients, although there is as yet no evidence of such shortening. The new phosphodiesterase inhibitor drugs are an exciting development in the treatment of heart failure, because they add a dimension to the treatment for patients who are not sufficiently improved by a regimen of digoxin, diuretics and ACE inhibitors. Any new heart failure medication should be able to improve rest and exercise haemodynamics, maintain its benefits when given orally and result in an improved exercise capacity and quality of life, and prolonged survival.
Similar content being viewed by others
References
Anderson J, Gilbert E, O’Connell J, Renlund D, Yanowitz F, et al. Beneficial effects of long term beta blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. Abstract. Journal of the American College of Cardiology 13: 117A, 1989
Antman E, Wenger T, Butler V, Haber E, Smith T. Treatment of 150 cases of life threatening digitalis intoxication with digoxin specific Fab antibody fragments. Circulation 81: 1744–1752, 1990
Bauman G, Felix S, Filcek S. Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects on hemodynamics and urine output. American Journal of Cardiology 65: 748–754, 1990
Binkley P, Van Fossen D, Nunziata E, Unverferth D, Leier C. Influence of positive inotropic therapy on pulsatile hydraulic load ventriculo-vascular coupling in congestive heart failure. Journal of the American College of Cardiology 15: 1127–1135, 1990
Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. Journal of the American Medical Association 259: 539–544, 1988
Captopril Multicenter Research Group. A placebo controlled trial of captopril in refractory chronic congestive heart failure. Journal of the American College of Cardiology 2: 755–763, 1983
Cohn J. New concepts in the mechanisms and treatment of congestive heart failure. American Journal of Cardiology 55: 1A–47A, 1985
Cohn J, Archibald D, Ziesche S, Franciosa J, Harston W, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New England Journal of Medicine 314: 1547–1552, 1986
Cohn J, Swedberg K, Kjekshus J. A symposium: advances in congestive heart failure. American Journal of Cardiology 62: 1A–83A, 1988
Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. New England Journal of Medicine 316: 1429–1435, 1987
DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant R, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New England Journal of Medicine 320: 677–683, 1989
Engelmeier R, O’Connell J, Walsh R, Rad N, Scanlon P, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double blind, randomized, placebo-controlled trial. Circulation 72: 536–546, 1985
Fowler M, Vaser J, Hopkins G, Minobe W, Bristow M. Assessment of the beta adrenergic receptor pathway in the intact failing human heart: progressive receptor down regulation and subsensitivity to agonist response. Circulation 74: 1290–1302, 1986
Franciosa JA, Wilen M, Ziesche S, Cohn J. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. American Journal of Cardiology 51: 831–836, 1983
Gage J, Rutman H, Lucido D, DeJemtel T. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367–373, 1986
Gerlag P, van Meijel J. High dose furosemide in the treatment of refractory congestive heart failure. Archives of Internal Medicine 148: 286–291, 1988
Gheorghiade M, Hall V, Larkier J, Goldstein S. Comparative hemodynamic and neurohumoral effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. Journal of the American College of Cardiology 13: 134–142, 1989
Heilbrunn S, Shah P, Bristow M, Valentine H, Ginsburg R, et al. Increased beta receptor density and improved hemodynamic response to catecholamine stimulation during long term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483–490, 1989
Hirakata H, Fouad-Tarazi F, Bumpus M, Khosla M, Healy B, et al. Angiotensins and the failing heart. Enhances positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circulation Research 66: 891–899, 1990
Hood W. Controlled and uncontrolled studies of phospho-diesterase III inhibitors in contemporary cardiovascular medicine. American Journal of Cardiology 63: 46A–53A, 1989
Hugenholtz P. A symposium: focus on heart failure —current experiences in basic research and clinical studies in dopexamine hydrochloride. American Journal of Cardiology 62: 1C–88C, 1988
Katz A. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73 (Suppl. III): 184–190, 1986
Katz A. The myocardium in congestive heart failure. American Journal of Cardiology 63: 12A–16A, 1989
Krell M, Kline E, Bates E, Hodgson J, Dilworth L, et al. Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure. American Heart Journal 112: 787–791, 1986
Lee D, Johnson R, Bingham J, Leahy M, Dinsmore R, et al. Heart failure in outpatients. A randomized trial of digoxin versus placebo. New England Journal of Medicine 306: 699–705, 1982
LeJemtel T, Keren G, Reis D, Sonnenblick E. The role of novel inotropic agents in the treatment of heart failure. Journal of Cardiovascular Pharmacology 8 (Suppl. 9): 547–554, 1986
Marantz P, Alderman M, Tobin J. Diagnostic heterogeneity in clinical trials for congestive heart failure. Annals of Internal Medicine 109: 55–61, 1988
Massie B, Ports T, Chatterjee K, Parmley W, Ostland J, et al. Long term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63: 269–278, 1981
McKee P, Castelli W, McNamara P, Kannel W. The natural history of congestive heart failure: the Framingham Study. New England Journal of Medicine 285: 1441–1446, 1971
Moran J, Rad N, Scanlon P. Long term survival of class IV heart failure patients treated with oral amrinone. Journal of Clinical Pharmacology 29: 494–499, 1989
Packer M. Physiologic determinants of survival in congestive heart failure. Circulation 75 (Suppl. IV): IV1–IV111, 1986
Packer M. Symposium on therapeutic challenges in the management of congestive heart failure: part I. Journal of the American College of Cardiology 12: 262–283, 1988
Packer M. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. American Journal of Cardiology 63: 41A–45A, 1989
Packer M. A symposium: hormone-electrolyte interactions in congestive heart failure. American Journal of Cardiology 65: 1E–52E, 1990
Packer M, Leier C. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 75 (Suppl. IV): IV55–IV63, 1987
Packer M, Medina N, Yushak M. Correction of dilutional hyponatremia in severe chronic heart failure by converting enzyme inhibition. Annals of Internal Medicine 100: 782–789, 1984
Parmley W, Ryden L. A symposium: congestive heart failure —advances in treatment. American Journal of Cardiology 63: 1D–37D, 1989
Pfeffer M, Lamas G, Vaughan D, Parisi A, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. New England Journal of Medicine 319: 80–86, 1988
Ribeiro J, White H, Arnold HM, Hartley LH, Colucci W. Exercise response before and after long term treatment with oral milrinone in patients with severe heart failure. American Journal of Medicine 81: 759–764, 1986
Shub C. Heart failure and abnormal ventricular function: pathophysiology and clinical correlation. Chest 96: 636–640, 906–914, 1989
Sleight P, Zanchetti A. Renin-angiotensin system on the heart. American Journal of Medicine 84: 1–162, 1988
Smith W. Epidemiology of congestive heart failure. American Journal of Cardiology 55: 3A–8A, 1985
Sonnenblick E. A symposium: the role of phospho-diesterase III inhibitors in contemporary cardiovascular medicine. American Journal of Cardiology 63: 1A–53A, 1989
Urata H, Healy B, Stewart R, Bumpus M, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circulation Research 66: 883–890, 1990
Wilson J, Schwartz S, St. John Sutton M, Ferraro N, Horowitz L, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. Journal of the American College of Cardiology 2: 403–410, 1983
Woodley S, Gilbert E, Anderson J, Deitchman D, Mealey P, et al. Differing effect of chronic beta blockade with bucindolol on cardiac function in patients with idiopathic versus ischemic cardiomyopathy. Abstract Circulation 80 (Suppl. II): 118, 1989
Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis —a new controversy regarding an old drug: the pitfalls of inappropriate methods. Circulation 73: 14–18, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moran, J.F. Risks and Benefits of the Treatment of Heart Failure. Drug-Safety 6, 277–284 (1991). https://doi.org/10.2165/00002018-199106040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199106040-00005